Gustave Roussy, Cancer Campus, Grand Paris Clinical Trials
Sponsors / Gustave Roussy, Cancer Campus, Grand Paris
Gustave Roussy, Cancer Campus, Grand Paris appears as lead sponsor on 220 trial records in ClinicalTrials.gov. The portfolio currently includes 40 recruiting studies, 12 active non-recruiting studies, and 73 completed studies. 24 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include slow or insufficient recruitment, efficacy or futility findings. Cumulative planned enrollment across all listed trials is 217,843 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.
220
Total Trials
40
Recruiting
12
Other Active
73
Completed
24
Terminated / Withdrawn
217,843
Total Enrollment
Termination reasons: Other75% · Recruitment13% · Efficacy8% · Safety4%
Recent Terminations
- Biliary Tract Cancer"Abandon of the partner, GSK"
- Breast Cancer"Abandon of the partner, ROCHE"
- Metastatic Renal Cell Carcinoma"Recruitment challenges: competition with another microbiome trial, patient refusal to join a dietary intervention study, poor tolerance of oral DPD (Grade 2 mucositis), and issues with organizing biological sample collection."
- Ovarian Cancer"Treatment availability issue: The manufacturer of AsiDNA™ decided to cease production to develop an improved version, and the contract ensuring access to this molecule has expired."
- Very High Risk Neuroblastoma"The Sponsor has been notified of an interruption in the international supply, and there is a possibility that 131I-mlBG would be unavailable to patients randomised to arm A of the trial"
- Peritoneal Carcinomatosis"No more experimental drugs available"
- Solid Tumor"Bankruptcy of partner: Clovis"
- Advanced Cancer"The part A of the trial has been completed according to the protocol. The part B has not been opened because of unfeasibility (experimental products not yet available)."
- High-risk Medulloblastoma
- Kidney Cancer
Active Trials (12 total)
- Thyroid Cancer PHASE3NCT03570021
- Mucositis Oral PHASE3NCT03983369
- NCT04932525
- Brain Tumor NANCT05890781
- NCT05476939
- NCT03313206
- NCT06479057
- NCT06828263
- NCT05267912
- NCT06402864
- Head and Neck Cancer PHASE2NCT04842162
- Adult Disease PHASE1/PHASE2NCT06007092
- Oligometastatic Disease PHASE1/PHASE2NCT06439888
- Breast Cancer PHASE3NCT06781996
- Breast Cancer PHASE2NCT07159451
- NCT06078384
- Kidney Cancer PHASE4NCT06934057
- NCT06505590
- NCT06840782
- Leukemia NANCT05691608